Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Dev Neurosci ; 36: 45-52, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24862851

ABSTRACT

Caffeine is the psychostimulant most consumed worldwide. However, little is known about its effects during fetal brain development. In this study, adult female Wistar rats received caffeine in drinking water (0.1, 0.3 and 1.0 g/L) during the active cycle in weekdays, two weeks before mating and throughout pregnancy. Cerebral cortex and hippocampus from embryonic stages 18 or 20 (E18 or E20, respectively) were collected for immunodetection of the following synaptic proteins: brain-derived neurotrophic factor (BDNF), TrkB receptor, Sonic Hedgehog (Shh), Growth Associated Protein 43 (GAP-43) and Synaptosomal-associated Protein 25 (SNAP-25). Besides, the estimation of NeuN-stained nuclei (mature neurons) and non-neuronal nuclei was verified in both brain regions and embryonic periods. Caffeine (1.0 g/L) decreased the body weight of embryos at E20. Cortical BDNF at E18 was decreased by caffeine (1.0 g/L), while it increased at E20, with no major effects on TrkB receptors. In the hippocampus, caffeine decreased TrkB receptor only at E18, with no effects on BDNF. Moderate and high doses of caffeine promoted an increase in Shh in both brain regions at E18, and in the hippocampus at E20. Caffeine (0.3g/L) decreased GAP-43 only in the hippocampus at E18. The NeuN-stained nuclei increased in the cortex at E20 by lower dose and in the hippocampus at E18 by moderate dose. Our data revealed that caffeine transitorily affect synaptic proteins during fetal brain development. The increased number of NeuN-stained nuclei by prenatal caffeine suggests a possible acceleration of the telencephalon maturation. Although some modifications in the synaptic proteins were transient, our data suggest that caffeine even in lower doses may alter the fetal brain development.


Subject(s)
Brain/metabolism , Caffeine/toxicity , Central Nervous System Stimulants/toxicity , Fetal Development/drug effects , Nerve Tissue Proteins/metabolism , Prenatal Exposure Delayed Effects , Synapses/metabolism , Age Factors , Animals , Animals, Newborn , Brain/pathology , Brain-Derived Neurotrophic Factor/metabolism , Caffeine/metabolism , Dose-Response Relationship, Drug , Embryo, Mammalian , Female , Hedgehog Proteins/genetics , Hedgehog Proteins/metabolism , Nerve Tissue Proteins/genetics , Neurons/metabolism , Neurons/pathology , Pregnancy , Prenatal Exposure Delayed Effects/chemically induced , Prenatal Exposure Delayed Effects/pathology , Prenatal Exposure Delayed Effects/physiopathology , Rats , Rats, Wistar , Signal Transduction/drug effects , Synapses/drug effects
2.
J Alzheimers Dis ; 34(2): 509-18, 2013.
Article in English | MEDLINE | ID: mdl-23241554

ABSTRACT

Intracerebroventricular (icv) streptozotocin (STZ) administration induces pathological and behavioral alterations similar to those observed in Alzheimer's disease (AD) and is thus considered an experimental model of sporadic AD. Since caffeine (an adenosine receptor antagonist) and selective antagonists of adenosine A2A receptors modify the course of memory impairment in different amyloid-ß-based experimental models of AD, we now tested the impact of caffeine on STZ-induced dementia and associated neurodegeneration in the hippocampus as well as on the expression and density of adenosine receptors. Adult male rats received a bilateral infusion of saline or STZ (3 mg/kg, icv), which triggered memory deficits after four weeks, as gauged by impaired object recognition memory. This was accompanied by a reduced NeuN immunoreactivity in the hippocampal CA1 region and an increased expression and density of adenosine A2A receptors (A2AR), but not A1R, in the hippocampus. Caffeine consumption (1 g/L in the drinking water starting 2 weeks before the STZ challenge) prevented the STZ-induced memory impairment and neurodegeneration as well as the upregulation of A2AR. These findings provide the first demonstration that caffeine prevents sporadic dementia and implicate the control of central A2AR as its likely mechanism of action.


Subject(s)
Caffeine/administration & dosage , Dementia/prevention & control , Disease Models, Animal , Hippocampus/drug effects , Memory Disorders/prevention & control , Receptor, Adenosine A2A , Adrenergic alpha-2 Receptor Antagonists/administration & dosage , Animals , Dementia/metabolism , Dementia/pathology , Hippocampus/metabolism , Hippocampus/pathology , Male , Memory Disorders/pathology , Neurons/drug effects , Neurons/pathology , Rats , Rats, Wistar , Receptor, Adenosine A2A/biosynthesis , Up-Regulation/drug effects , Up-Regulation/physiology
3.
Neuropharmacology ; 64: 153-9, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22841916

ABSTRACT

Beneficial effects of caffeine on memory processes have been observed in animal models relevant to neurodegenerative diseases and aging, although the underlying mechanisms remain unknown. Because brain-derived neurotrophic factor (BDNF) is associated with memory formation and BDNF's actions are modulated by adenosine receptors, the molecular targets for the psychostimulant actions of caffeine, we here compare the effects of chronic caffeine (1 mg/mL drinking solution for 30 days) on short- and long term memory and on levels of hippocampal proBDNF, mature BDNF, TrkB and CREB in young (3 month old) and middle-aged (12 month old) rats. Caffeine treatment substantially reduced i) age-related impairments in the two types of memory in an inhibitory avoidance paradigm, and ii) parallel increases in hippocampal BDNF levels. In addition, chronic caffeine increased proBDNF and CREB concentrations, and decreased TrkB levels, in hippocampus regardless of age. These data provide new evidence in favor of the hypothesis that modifications in BDNF and related proteins in the hippocampus contribute to the pro-cognitive effects of caffeine on age-associated losses in memory encoding. This article is part of a Special Issue entitled 'Cognitive Enhancers'.


Subject(s)
Aging , Brain-Derived Neurotrophic Factor/metabolism , Caffeine/therapeutic use , Cognitive Dysfunction/prevention & control , Hippocampus/metabolism , Neurons/metabolism , Nootropic Agents/therapeutic use , Protein Precursors/metabolism , Animals , Avoidance Learning , Behavior, Animal , Central Nervous System Stimulants/therapeutic use , Cognitive Dysfunction/metabolism , Cyclic AMP Response Element-Binding Protein/metabolism , Hippocampus/growth & development , Male , Memory, Long-Term , Memory, Short-Term , Neural Inhibition , Rats , Rats, Wistar , Receptor, trkB/metabolism
4.
Prog Neuropsychopharmacol Biol Psychiatry ; 36(1): 198-204, 2012 Jan 10.
Article in English | MEDLINE | ID: mdl-22064330

ABSTRACT

Physical exercise protocols have varied widely across studies raising the question of whether there is an optimal intensity, duration and frequency that would produce maximal benefits in attenuating symptoms related to anxiety disorders. Although physical exercise causes modifications in neurotransmission systems, the involvement of neuromodulators such as adenosine has not been investigated after chronic exercise training. Anxiety-related behavior was assessed in the elevated plus-maze in adult and middle-aged rats submitted to 8 weeks of treadmill running 1, 3 or 7 days/week. The speed of running was weekly adjusted to maintain moderate intensity. The hippocampal adenosine A1 and A2A receptors densities were also assessed. Treadmill running protocol was efficient in increasing physical exercise capacity in adult and middle-aged rats. All frequencies of treadmill running equally decreased the time spent in the open arms in adult animals. Middle-aged treadmill control rats presented lower time spent in the open arms than adult treadmill control rats. However, treadmill running one day/week reversed this age effect. Adenosine A1 receptor was not changed between groups, but treadmill running counteracted the age-related increase in adenosine A2A receptors. Although treadmill running, independent from frequency, triggered anxiety in adult rats and treadmill running one day/week reversed the age-related anxiety, no consistent relationship was found with hippocampal adenosine receptors densities. Thus, our data suggest that as a complementary therapy in the management of mental disturbances, the frequency and intensity of physical exercise should be taken into account according to age. Besides, this is the first study reporting the modulation of adenosine receptors after chronic physical exercise, which could be important to prevent neurological disorders associated to increase in adenosine A2A receptors.


Subject(s)
Anxiety/metabolism , Exercise Test , Hippocampus/metabolism , Receptor, Adenosine A1/metabolism , Receptor, Adenosine A2A/metabolism , Running/physiology , Aging/physiology , Aging/psychology , Animals , Anxiety/psychology , Exercise Test/methods , Exercise Test/psychology , Male , Rats , Rats, Wistar , Running/psychology
5.
Prog Neuropsychopharmacol Biol Psychiatry ; 35(1): 169-76, 2011 Jan 15.
Article in English | MEDLINE | ID: mdl-21044657

ABSTRACT

Methylphenidate (MPH) is the preferred treatment used for attention-deficit/hyperactivity disorder (ADHD). Recently, misuse for MPH due to its apparent cognitive enhancer properties has been reported. Adenosine is a neuromodulator known to exert influence on the dopaminergic neurotransmission, which is the main pharmacological target of MPH. We have reported that an overdosage of MPH up-regulates adenosine A(1) receptors in the frontal cortex, but this receptor was not involved in its anxiolytic effects. In this study, the role of adenosine A(1) receptor was investigated on MPH-induced effects on aversive and recognition memory in adult mice. Adult mice received acute and chronic (15 days) administration of methylphenidate (5mg/kg, i.p.), or an acute overdosage (50mg/kg, i.p) in order to model misuse. Memory was assessed in the inhibitory avoidance and object recognition task. Acute administration 5mg/kg improved whereas 50mg/kg disrupted recognition memory and decreased performance in the inhibitory avoidance task. Chronic administration did not cause any effect on memory, but decreased adenosine A(1) receptors immunocontent in the frontal cortex. The selective adenosine A(1) receptor antagonist, (DPCPX 1mg/kg, i.p.), prevented methylphenidate-triggered recognition memory impairment. Our findings showed that recognition memory rather than aversive memory was differently affected by acute administration at both doses. Memory recognition was fully impaired by the overdosage, suggesting that misuse can be harmful for cognitive functions. The adenosinergic system via A(1) receptors may play a role in the methylphenidate actions probably by interfering with dopamine-enhancing properties of this drug.


Subject(s)
Central Nervous System Stimulants/toxicity , Memory Disorders , Methylphenidate/toxicity , Receptor, Adenosine A1/metabolism , Recognition, Psychology/drug effects , Adenosine A1 Receptor Antagonists/administration & dosage , Analysis of Variance , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Schedule , Escape Reaction/drug effects , Exploratory Behavior/drug effects , Gene Expression Regulation/drug effects , Hippocampus/drug effects , Hippocampus/metabolism , Inhibition, Psychological , Male , Memory Disorders/chemically induced , Memory Disorders/metabolism , Memory Disorders/prevention & control , Mice , Recognition, Psychology/physiology , Xanthines/administration & dosage
6.
Brain Res ; 1357: 62-9, 2010 Oct 21.
Article in English | MEDLINE | ID: mdl-20699089

ABSTRACT

In recent years misuse of methylphenidate (MPH) has been reported. The main pharmacological target of methylphenidate is the dopaminergic system. Adenosine is a neuromodulator that influences the dopaminergic neurotransmission, but studies on MPH and adenosine are still lacking. In this study, adult mice were acutely treated with MPH (5mg/kg, i.p.) and to model misuse, they received an acute overdosage (50mg/kg, i.p). The involvement of adenosine A(1) receptors in anxiety-related behavior and locomotor and exploratory activity was examined. The administration of methylphenidate (5 and 50mg/kg) 30 min before the exposure to open field arena did not modify locomotor activity. The anxiolytic-like behavior was observed with both doses of MPH as revealed by the increase on the number of entries and the time spent in the open arms in the elevated plus-maze. Pre treatment with selective adenosine A(1) receptor antagonist (DPCPX 1mg/kg, i.p.) did not prevent anxiolytic effect caused by MPH 50mg/kg. Immunoblotting of frontal cortex and hippocampal extracts revealed that MPH 50mg/kg increased 88% adenosine A(1) receptor density in the frontal cortex. Extracts from hippocampus did not reveal any differences in the adenosine A(1) receptor density. Our findings ruled out the participation of adenosine A(1) receptors on the MPH-triggered anxiolytic effects. However, the density of adenosine A(1) receptors increased in a brain area strictly involved in the MPH-mediated effects. Thus, the adenosinergic system may play a role in the methylphenidate actions in the central nervous system.


Subject(s)
Anxiety/drug therapy , Frontal Lobe/metabolism , Hippocampus/metabolism , Methylphenidate/pharmacology , Motor Activity/drug effects , Receptor, Adenosine A1/metabolism , Adenosine A1 Receptor Antagonists/pharmacology , Analysis of Variance , Animals , Anxiety/metabolism , Blotting, Western , Central Nervous System Stimulants/pharmacology , Male , Mice , Motor Activity/physiology , Xanthines/pharmacology
7.
Behav Brain Res ; 214(2): 254-9, 2010 Dec 25.
Article in English | MEDLINE | ID: mdl-20553765

ABSTRACT

Caffeine is a psychostimulant with positive effects on cognition. Recent studies have suggested the participation of the cholinergic system in the effects of caffeine on wakefulness. However, there are few studies assessing the contribution of cholinergic system in the cognitive enhancer properties of caffeine. In the present study, the effects of a dose and schedule of administration of caffeine that improved memory recognition were investigated on scopolamine-induced impairment of memory in adult mice. Inhibitory avoidance and novel object recognition tasks were used to assess learning and memory. Caffeine (10mg/kg, i.p.) was administered during 4 consecutive days, and the treatment was interrupted 24h before scopolamine administration (2mg/kg, i.p.). Scopolamine was administered prior to or immediately after training. Short-term and long-term memory was evaluated in both tasks. In the novel object recognition task, pre treatment with caffeine prevented the disruption of short- and long-term memory by scopolamine. In the inhibitory avoidance task, caffeine prevented short- but not long-term memory disruption by pre training administration of scopolamine. Caffeine prevented short- and long-term memory disruption by post training administration of scopolamine. Both treatments did not affect locomotor activity of the animals. These findings suggest that acute treatment with caffeine followed by its withdrawal may be effective against cholinergic-induced disruption of memory assessed in an aversive and non-aversive task. Finally, our results revealed that the cholinergic system is involved in the positive effects of caffeine on cognitive functions.


Subject(s)
Avoidance Learning/drug effects , Caffeine/pharmacology , Memory/drug effects , Recognition, Psychology/drug effects , Scopolamine/antagonists & inhibitors , Animals , Caffeine/administration & dosage , Drug Administration Schedule , Drug Interactions , Male , Mice , Mice, Inbred Strains , Motor Activity/drug effects , Scopolamine/pharmacology
8.
Toxicol Sci ; 113(2): 434-43, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19926633

ABSTRACT

Diphenyl diselenide (PhSe)(2) is a selenium organic compound that has been described to inhibit glutamate binding at synaptic membranes and uptake into cortical slices, but there are no studies about its effects on glutamate transporters and related synaptic proteins. Hippocampal slices from rats treated acutely with (PhSe)(2) (1, 10, and 100 mg/kg, oral route) were evaluated on glutamate uptake, redox state, the immunocontent of glial (glutamate/aspartate transporter [GLAST] and glutamate transporter type I [GLT1]), neuronal (excitatory amino acid carrier 1 [EAAC1]), and vesicular (vesicular glutamate transporter 1 [VGLUT1]) glutamate transporters. Besides, cell viability was evaluated by glial fibrillar acid protein (GFAP) and synaptosomal-associated protein 25 (SNAP-25) immunocontent and 4', 6-diamidino-2-phenylindole (DAPI) and Fluoro Jade C staining. Hippocampal slices from rats treated with (PhSe)(2) exhibited a nondose-dependent inhibition of glutamate uptake (53, 38, and 45%, respectively). All doses increased EAAC1, decreased SNAP-25, did not modify GLT1 immunocontent, and there was no evidence of oxidative stress. (PhSe)(2) (100 mg/kg) increased 32% GLAST, decreased 34% VGLUT1, and 21% GFAP immunocontent. Besides, (PhSe)(2) (100 mg/kg) decreased by 25% GFAP-stained astrocytes and 27% DAPI-stained cells in the CA1 subfield. Our results suggest that the increase of EAAC1 and GLAST immunocontent by (PhSe)(2) might be a compensatory mechanism by surviving cells in order to reduce extracellular glutamate levels, avoiding possible neurotoxic effects. The impairment of glutamate uptake by the highest dose of (PhSe)(2) seems to be related to a decrease on VGLUT1, SNAP-25, and damage to astrocytes. Since there were no signs of oxidative stress, our findings revealed that depending on the dose, acute administration of (PhSe)(2) causes modifications in important synaptic-related proteins and damage to the astrocytes, and these events must be taken into account in its pharmacological properties.


Subject(s)
Benzene Derivatives/toxicity , Glial Fibrillary Acidic Protein/metabolism , Glutamic Acid/metabolism , Hippocampus/metabolism , Organoselenium Compounds/toxicity , Synaptosomal-Associated Protein 25/metabolism , Amino Acid Transport System X-AG/immunology , Amino Acid Transport System X-AG/metabolism , Animals , Glial Fibrillary Acidic Protein/immunology , In Vitro Techniques , Male , Oxidative Stress/drug effects , Rats , Rats, Wistar , Synaptosomal-Associated Protein 25/immunology , Toxicity Tests, Acute , Vesicular Glutamate Transport Proteins/immunology , Vesicular Glutamate Transport Proteins/metabolism
9.
Neurochem Int ; 53(3-4): 89-94, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18620014

ABSTRACT

Caffeine is one of the most psychostimulants consumed all over the world that usually presents positive effects on cognition. In this study, effects of caffeine on mice performance in the object recognition task were tested in different intertrial intervals. In addition, it was analyzed the effects of caffeine on brain derived neurotrophic factor (BDNF) and its receptor, TrkB, immunocontent to try to establish a connection between the behavioral finding and BDNF, one of the neurotrophins strictly involved in memory and learning process. CF1 mice were treated during 4 consecutive days with saline (0.9g%, i.p.) or caffeine (10mg/kg, i.p., equivalent dose corresponding to 2-3 cups of coffee). Caffeine treatment was interrupted 24h before the object recognition task analysis. In the test session performed 15min after training session, caffeine-treated mice recognized more efficiently both the familiar and the novel object. In the test session performed 90min and 24h after training session, caffeine did not change the time spent in the familiar object but increased the object recognition index, when compared to control group. Western blotting analysis of hippocampus from caffeine-treated mice revealed an increase in BDNF and TrkB immunocontent, compared to their saline-matched controls. Phospho-CREB immunocontent did not change with caffeine treatment. Our results suggest that acute treatment with caffeine improves recognition memory, and this effect may be related to an increase of the BDNF and TrkB immunocontent in the hippocampus.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Caffeine/pharmacology , Cyclic AMP Response Element-Binding Protein/metabolism , Hippocampus/metabolism , Pattern Recognition, Visual/drug effects , Receptor, trkB/metabolism , Animals , Central Nervous System Stimulants/pharmacology , Cognition/drug effects , Cognition/physiology , Dose-Response Relationship, Drug , Memory/drug effects , Memory/physiology , Mice , Neuropsychological Tests , Pattern Recognition, Visual/physiology , Phosphorylation/drug effects , Recognition, Psychology/drug effects , Recognition, Psychology/physiology , Signal Transduction/drug effects , Signal Transduction/physiology , Up-Regulation/drug effects , Up-Regulation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...